Literature DB >> 20175030

Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis.

Tania Roskams1, Masamichi Kojiro.   

Abstract

Recently, an East-West consensus on the histopathologic criteria for the diagnosis of high-grade dysplastic nodules (HGDN) versus early hepatocellular carcinoma (HCC) was reached. Next to classical morphologic criteria such as nucleocytoplasmic ratio, thickness of cell plates, mitotic index, and architectural disturbance like acinar structures, one of the most relevant criteria to diagnose early HCC is stromal invasion. Because a structured basement membrane is lacking along the hepatocytes in the liver, invasion cannot be defined as tumor growth through the basement membrane as in other tissues. However, the number of portal tracts that are present in a nodule gradually decrease because the tumoral hepatocytes start to show a destructive invading growth pattern in the mesenchyma/stroma of these portal tracts. This feature of stromal invasion is however sometimes difficult to recognize in needle biopsies because included portal tracts can be absent. Therefore, other diagnostic criteria are necessary. Based on molecular profiling, several additional markers for early malignant HCC have been found recently. Glypican-3, heat shock protein 70, and glutamine synthetase have been already validated and can be used as a panel of stains to confirm the pathologist's histopathologic diagnosis and to solve difficult cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20175030     DOI: 10.1055/s-0030-1247129

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  46 in total

Review 1.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

Review 2.  Histopathologic features of hepatocellular carcinoma.

Authors:  Elizabeth M Brunt
Journal:  Clin Liver Dis (Hoboken)       Date:  2013-01-23

3.  Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.

Authors:  Anna Darnell; Jordi Rimola; Ernest Belmonte; Enric Ripoll; Ángeles Garcia-Criado; Carla Caparroz; Álvaro Díaz-González; Ramón Vilana; María Reig; Carmen Ayuso; Jordi Bruix; Alejandro Forner
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

Review 4.  Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma.

Authors:  Tiffany Hennedige; Sudhakar K Venkatesh
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

5.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

Review 6.  The clinical role of 'liquid biopsy' in hepatocellular carcinoma.

Authors:  Jessica A Howell; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-11-30

Review 7.  Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.

Authors:  Norihide Yoneda; Osamu Matsui; Satoshi Kobayashi; Azusa Kitao; Kazuto Kozaka; Dai Inoue; Kotaro Yoshida; Tetsuya Minami; Wataru Koda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2019-02-02       Impact factor: 2.374

8.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

9.  Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamsters.

Authors:  Guo Chen; Zhi-Kai Dai; Rong-Gan Liang; Sheng-Jun Xiao; Song-Qing He; Hai-Lu Zhao; Qing Xu
Journal:  Exp Ther Med       Date:  2011-12-02       Impact factor: 2.447

Review 10.  Hepatocellular carcinoma--resection or transplant?

Authors:  Sheung Tat Fan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-09-11       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.